BiovaxID lymphoma vaccine to be featured at ASH Meeting

NewsGuard 100/100 Score
Nov 16 2010

Biovest International, Inc. (OTCQB: BVTI) today announced that BiovaxID®, Biovest's personalized lymphoma vaccine, will be featured in an oral presentation at the American Society of Hematology (ASH) Annual Meeting on Monday, December 6th in Orlando, Florida.

“Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration in Follicular Lymphoma Patients.”

Stephen J. Schuster, M.D., Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, will deliver the BiovaxID presentation titled, "Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration in Follicular Lymphoma Patients."

The abstract can be accessed at the ASH website by visiting: http://ash.confex.com/ash/2010/webprogram/Paper34600.html

Source:

Biovest International, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Bivalent COVID-19 vaccine boosts immunity but needs to be updated
Equal vaccination rates found among undocumented Latinx ER patients in the U.S.
Study shows potential for universal flu vaccine with broad antibody response
Researchers identify key barriers and outline recommendations for vaccine uptake in pregnant women
Novel vaccine approach targets AML and other blood cancers
New study offers promising targets for universal influenza B vaccine
Novel vaccine approach effective against all virus strains
MSU team creates a promising vaccine candidate for antibiotic-resistant bacteria

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses